BPH GlobalASX:BP8 Days Payable is 96.02 as of Dec. 2025, which is 653% above its 10-year median of 12.75. The stock has 6 warning signs investors should review. Among 920 Drug Manufacturers companies, BPH Global ranks better than 86.41% on this metric.
BPH Global's average Accounts Payable for the
six
months ended in Dec. 2025 was A$0.76 Mil. BPH Global's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$1.44 Mil.
Hence, BPH Global's Days Payable for the
six
months ended in Dec. 2025 was 96.02.
The historical rank and industry rank for BPH Global's Days Payable or its related term are showing as below:
ASX:BP8'
s Days Payable Range Over the Past 10 Years
Min: 0.26 Med: 12.75 Max: 870.38
Current: 212.7
During the past 13 years, BPH Global's highest Days Payable was 870.38. The lowest was 0.26. And the median was 12.75.
ASX:BP8's Days Payable is ranked better than 86.41% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs ASX:BP8: 212.70
BPH Global's Days Payable
declined
from Dec. 2024 (3,431.00) to Dec. 2025 (96.02).
It may suggest that BPH Globalaccelerated paying its suppliers.
BPH Global Days Payable Related Terms
BPH Global Days Payable Historical Data
* Premium members only.
The historical data trend for BPH Global's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Days Payable distribution charts can be found below:
* The bar in red indicates where BPH Global's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BPH Global's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a Days Payable of 96.02 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BPH Global and its competitors. This is 653% above median its historical median of 12.75. Over the past decade, BPH Global's Days Payable has ranged from 0.26 to 870.38. According to the industry distribution chart, BPH Global ranks #125 out of 920 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is BPH Global's Days Payable too high?
BPH Global's current Days Payable of 96.02 is 653% above median its 10-year median of 12.75. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 870.38. The Drug Manufacturers industry median Days Payable is 90.84. BPH Global's value of 96.02 is 5.7% above this industry median. Based on the distribution chart, BPH Global ranks #125 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BPH Global's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #125 out of 920 companies for Days Payable. This places BPH Global in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. BPH Global's value of 96.02 is 5.7% above this benchmark. Historically, BPH Global's own Days Payable has ranged from 0.26 to 870.38 over the past decade. While the company's 10-year median is 12.75 vs. the industry median of 90.84, BPH Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current Days Payable of 96.02 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Days Payable is 96.02, which is 653% above median its own 10-year median of 12.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Days Payable of 96.02. The current Days Payable is 96.02, which is 653% above median its 10-year median of 12.75 and 5.7% above the Drug Manufacturers industry median of 90.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Days Payable is 96.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 